摘要
目的比较和分析肺癌治疗药物在国家启动医保谈判前后的使用变化情况,研究一系列政策对肺癌用药的影响。方法运用描述性统计方法,分析北京大学人民医院2014-2020年肺癌患者的基本情况和治疗药物的变化趋势,并结合全国医药信息网中肺癌治疗药物的医院采购数据进行综合分析。结果2014-2020年肺癌患者人均总费用整体呈现先上升后下降趋势,在国家药品医保谈判前不断增长,谈判后逐步降低。2017年之后,血管内皮生长因子/血管内皮生长因子受体(VEGF/VEGFR)抑制剂和表皮生长因子受体(EGFR)酪氨酸激酶抑制剂等解剖学、治疗学及化学分类系统(ATC)小类用量明显增加,单克隆抗体品种数也在增多。奥希替尼、安罗替尼、阿来替尼、克唑替尼等医保目录药品的用药频度(DDDs)上升趋势明显,日均费用明显降低。结论近年来,肺癌患者住院天数持续缩短,用药结构发生显著变化。国家医保目录的调整使更多的肺癌创新药呈现“量升价降”趋势。
Objective To compare and analyze the changes in the use of lung cancer therapeutic drugs before and after the national initiation of health insurance negotiations,and to study the impact of a series of policies on the use of lung cancer drugs.Methods Descriptive statistical methods were used analyze the basic situation of lung cancer patients and the changes of corresponding therapeutic drugs in Peking University People's Hospital from 2014 to 2020,as well as to the hospital procurement data of lung cancer therapeutic drugs in the database of the Chinese Medicine Economic Information.Results From 2014 to 2020,the total cost per capita of lung cancer patients showed a trend of first increasing and then decreasing,increasing before the national drug negotiation and gradually decreasing after the negotiation.After 2017,the use of small ATC categories such as VEGF/VEGFR inhibitors and EGFR tyrosine kinase inhibitors increased significantly,along with a rise in the number of monoclonal antibody varieties.The DDDs of osimertinib,anlotinib,alectinib,crizotinib and other drugs in the medical insurance list increased significantly,and the average daily cost decreased significantly.Conclusion The number of hospitalization days for lung cancer patients had continued to shorten in recent years,and the structure of drug use had changed significantly.The adjustment of the medical insurance catalog had led to more innovative lung cancer drugs showing the trend of volume up and price down.
作者
刘爽
吴燕秋
易洪彬
蒯丽萍
徐冬艳
汤建华
LIU Shuang;WU Yanqiu;YI Hongbin;KUAI Liping;XU Dongyan;TANG Jianhua(Department of Pharmacy,Children’s Hospital Affiliated to Zhengzhou University,Zhengzhou 450018,China;Peking University People's Hospital,Beijing 100044,China;School of Business Administration,Shenyang Pharmaceutical University,Shenyang 110016,China;Science and Technology Development Center of Chinese Pharmaceutical Association,Beijing 100022,China;Department of Pharmacy,The First Affiliated Hospital of Hebei North University,Zhangjiakou 075000,China)
出处
《药学实践与服务》
2026年第3期152-159,共8页
Journal of Pharmaceutical Practice and Service
基金
河北省医研企联合创新专项课题计划(LH20250183)。
关键词
肺癌
使用频度
用药金额
日均费用
lung cancer
defined daily doses
medication cost
defined daily dose cost
